McCormick & Company, Incorporated (NYSE: MKC) — A Decade-Cheap Spice Monopoly Wagering Itself on Unilever’s Pantry

Report date: June 21, 2026 Price (as of 2026-06-18 close): ~$46.64/share Market cap: ~$12.5B · Enterprise value (live recompute): ~$16.8B · Net debt: ~$3.9B (pre-deal) · Shares: ~268.4M (dual class: MKC non-voting + MKC.V voting) Sector / classification: Consumer Staples → Packaged Foods → Spices, Seasonings, Condiments & B2B Flavor Solutions CIK: 0000063754 · HQ: Hunt Valley, Maryland · FY-end: November 30 · Founded: 1889

The body of this article (Executive Summary onward) is written to be position-free and carries no investment recommendation and no price target. The single, deliberately fenced-off exception is the Author’s Take block immediately below, which is a subjective view.

⚡ Author’s Take

This block is the author’s own subjective opinion. It is general information and not investment advice. Everything from the Executive Summary onward is position-free and carries no price target except where this block is quoted.

Verdict: HOLD / accumulate-on-weakness — a genuinely cheap wide-moat franchise wrapped in a doubted, self-diluting mega-merger. Own the standalone value in the ~$42–48 zone (≈12x EV/EBITDA, ~15x adj. EPS, a safe ~4% aristocrat yield); add on a sub-$44 deal-fear washout; NOT a short into a ~13.8x-struck deal with an activist on the register. Conviction: medium.

Tag: “The cheapest spices in a decade — now wagering the franchise on Unilever’s leftovers.”

McCormick is two things at once, and the tape is pricing the worse of them. The first is a real, durable, Greenwald-style demand-captivity franchise: the #1 global spice and seasoning brand (McCormick, French’s, Frank’s RedHot, Cholula, OLD BAY), a 40-consecutive-year dividend aristocrat earning an ~18.6% Consumer-segment operating margin, now trading at the cheapest multiple in its own decade — ~15.5x adjusted EPS and ~12x EV/EBITDA versus an own-history that lived at 22–33x, ~51% below its 2022 peak, on a 0.2 beta. On the standalone math alone this is fair-leaning-cheap: the price embeds permanent volume stagnation and no margin recovery, which is too pessimistic for a brand-habit staple that “flavors calories while others compete for them.” The second thing is the problem. On 2026-03-31 management announced “Project Apollo” — a Reverse-Morris-Trust combination with Unilever’s Foods business (Knorr, Hellmann’s, Maille) that dilutes existing MKC holders to 35% of a ~$60B combined company, hands Unilever $15.7B of cash funded by a $15.7B bridge plus a $2B term loan, re-levers a just-deleveraged balance sheet back to ~4x, and won’t close until ~mid-2027. Management is, in effect, using its own decade-trough valuation as the currency to issue away two-thirds of the company.

What the market is mispricing is the interaction of these two facts. The deal is struck at ~13.8x EBITDA for both sides, so on paper it is fair and the entire value-add is the ~$600M of promised synergies (~$7–10/share to MKC’s 35% stake). But the stock has kept falling since the announcement ($53 → ~$46) and Terry Smith’s Fundsmith publicly dumped Unilever over it — the market is discounting both deal-break risk (a $60B cross-border combo, mid-2027 close, antitrust, $17.7B of financing) and the structural downgrade of swapping 100% of a clean, focused, ~12x spice compounder for 35% of a 4x-levered conglomerate that imports mature, private-label-exposed Knorr/Hellmann’s volumes. Here is the asymmetry I like: at ~$46.64 the tape is pricing something worse than both the standalone base case (~$50–62) and the deal-at-strike mark (~$78). Deal-success and deal-break could each plausibly resolve higher than spot — a rare configuration. This is an abandoned-value, low-volatility, rate-sensitive defensive staple (beta 0.2 — it bleeds, it does not crash), not a falling knife and not a momentum name, now carrying a long-dated, un-pinned merger overhang and an event-driven activist (Toms Capital) who just showed up. Flip me bullish: the deal is repriced in MKC holders’ favor (a bigger synergy number quantified into EPS, a collar, or — Toms’s likely lever — withdrawal in favor of buybacks and a pure-play) and organic volume keeps inflecting. Flip me bearish: organic volume rolls over into a genuine private-label/GLP-1 structural decline and the deal closes on time at a conglomerate multiple with the integration slipping — the KHC outcome, at 4x leverage.

📈 Stock Price Action — Five-Year Event Map

Factual price history — no recommendation, no price target. Price moves are FACT; attributed causes are INTERPRETATION.

The arc. A five-year round-trip and near-halving. McCormick (split/dividend-adjusted) peaked near ~$95 in April 2022 (unadjusted ~$104), ground lower for three years, and broke down to a ~$45.6 trough in May 2026, closing at $46.64 on 2026-06-18. The 52-week range is roughly $44.8–$75.9; the stock sits ~51% below its five-year peak, with a lifetime maximum drawdown of ~52%. The defining recent event is the 2026-03-31 Unilever-Foods deal announcement, after which the stock continued lower — the market’s verdict on a transformational, self-diluting transaction.

Each numbered move is corroborated by a five-year price series cross-referenced to earnings prints, the FY guide, the 8-K record, and the news feed (see the Source Appendix). The opportunity/mispricing judgment belongs to Author’s Take above; this block states only what happened and why.

1. Executive Summary

McCormick is the global leader in spices, seasonings, condiments, and flavors, operating two segments: Consumer (branded retail — McCormick, French’s, Frank’s RedHot, Cholula, Lawry’s, OLD BAY, Zatarain’s, Gourmet Garden, plus Ducros/Schwartz/Kamis in EMEA) and Flavor Solutions (B2B seasoning blends, coatings, and compound flavors sold to multinational food manufacturers and foodservice operators). FY2025 (ended 2026-11-30) revenue was $6,840.3M (+1.7% YoY), split Consumer 57.8% / Flavor Solutions 42.2%; Consumer generated ~67% of segment operating profit at an 18.6% margin versus Flavor Solutions’ 12.4% — the ~6-point gap is the quantified value of the brand moat. Consolidated gross margin was 37.9%, operating margin 16.0%, GAAP diluted EPS $2.93 (adjusted ~$3.00).

The franchise is genuinely good and genuinely cheap. McCormick holds the #1 global branded position in an infrequent, low-ticket, habitual category, with category-captaincy shelf control and ~38% gross margins that have survived a brutal cost cycle. Yet the stock has de-rated ~51% from its 2022 peak to ~$46.64, a decade-low ~15.5x adjusted EPS / ~12x EV/EBITDA / ~4% dividend yield — well below its own historical 22–33x range and beneath premium staples peers (HSY ~21x, MDLZ ~18x EV/EBITDA), though above broken-value names (KHC ~7.8x, INGR ~6.8x). The de-rating reflects a real problem: EPS has been flat for five years ($2.78 in FY2020 → $2.93 in FY2025) as ~4% revenue growth — almost entirely price, not volume — was offset by inflation-driven gross-margin compression (41.1%→35.8% trough→37.9%) and rising interest expense from a serial-acquisition debt load.

The dominant fact, however, is a pending transformational deal. On 2026-03-31 McCormick announced “Project Apollo,” a Reverse-Morris-Trust combination with Unilever’s Foods business (Knorr, Hellmann’s, Maille, bouillon, dressings/condiments). McCormick issues a fixed number of shares such that, post-close, Unilever and its shareholders own 65% and existing McCormick holders own 35% of the combined ~$60B-equity company; Unilever also receives $15.7B in cash (financed by a $15.7B 364-day bridge plus a $2.0B term loan). Both sides were struck at ~13.8x CY2025 EBITDA; management targets $600M of run-rate cost synergies, net leverage ~4x at close declining to ~3x within two years, a maintained ~60% dividend payout, a secondary European listing, and a mid-2027 close subject to a McCormick shareholder vote and regulatory approval. Activist Toms Capital disclosed a stake in early June 2026; Fundsmith’s Terry Smith publicly exited Unilever in protest of the structure.

The verdicts that follow: the spices/flavor industry is structurally good but maturing (concentrated, branded, pricing-powered — better than center-store CPG, but capped by private-label and packaged-food malaise); the moat is a real but narrowing demand-captivity advantage on Consumer and a contestable switching-cost position in Flavor Solutions; growth is low-quality-trending-better (five years of flat EPS, but a genuine FY2025 volume inflection); financial quality is moderate (clean QoE, real ~$740M FCF, but consolidated ROIC ~8.7% ≈ WACC — the moat is not compounding per share); capital allocation is mediocre and now high-stakes (serial lever-up/de-lever M&A with no return-on-capital incentive metric, capped by a transformational RMT that re-levers to 4x and dilutes holders to a minority). At ~$46.64 the market prices MKC below both its standalone base case and the deal’s struck value — a special situation in which the principal risks (deal-break, integration, structural volume decline) are partly offset by a decade-cheap entry into a real franchise.

2. Business Overview

2.1 What McCormick makes and sells

Founded in 1889 and headquartered in Hunt Valley, Maryland, McCormick manufactures, markets, and distributes flavor — spices, herbs, seasoning mixes, condiments, sauces, and compound flavors — to both retail consumers and food-industry customers. The FY2025 10-K reports two segments:

Consumer — 57.8% of FY2025 sales ($3,950.3M), ~67% of segment operating profit, 18.6% segment margin. The branded retail crown jewel. Core spices and seasonings under the flagship McCormick brand sit alongside a portfolio assembled over decades — French’s (mustard, #1 US) and Frank’s RedHot (the #1 US hot sauce, acquired in the 2017 RB Foods deal), Cholula (premium hot sauce, 2020), Lawry’s, OLD BAY, Zatarain’s, Stubb’s, Gourmet Garden, Thai Kitchen, and Simply Asia in the Americas; Ducros, Schwartz, Kamis, La Drogheria, and Vahiné in EMEA; and McCormick/DaQiao in Asia. Consumer is sold through grocery, mass-merchandise, warehouse-club, discount/drug, and e-commerce retailers — and, distinctively, McCormick also supplies private-label spices to many of the same retailers.

Flavor Solutions — 42.2% of FY2025 sales ($2,890.0M), ~33% of segment operating profit, 12.4% segment margin. The B2B leg: seasoning blends, coating systems, condiments, and compound flavors sold to multinational food manufacturers and foodservice operators (directly and via distributors). This is a customer-intimacy, co-development business — formulas embedded in customers’ branded products and QSR menu items, with relationships management describes as “active for decades.” It is lower-margin than Consumer but stickier per dollar of revenue, and it is the segment most exposed to the flavor-house competitors (Givaudan, IFF, Symrise, Sensient).

2.2 How it makes money; recurring vs. one-time; geography

McCormick is a branded-and-private-label consumer-products manufacturer plus a B2B flavor formulator. Revenue is overwhelmingly transactional (units sold at retail or to manufacturers), but the demand is unusually stable for a hardgoods-free staple: spices are consumable, repeatedly repurchased, and a trivial share of a household grocery basket — closer to a consumables annuity than to discretionary packaged food. There is no subscription layer; the “recurring” quality comes from habit (Consumer) and embedded formulas/qualification (Flavor Solutions).

Geographically, FY2025 sales were ~61% US / ~18% EMEA / ~21% other (~39% non-US). Customer concentration is real but not extreme: Walmart ~12% and PepsiCo ~12% of total company sales; the top-3 Flavor Solutions customers are ~49% of that segment’s sales — a structural vulnerability in B2B (a lost mandate is lumpy).

2.3 The portfolio is heavily acquired

McCormick’s modern shape is the product of three debt-funded acquisitions: RB Foods (French’s + Frank’s RedHot, 2017, ~$4.2B at ~20x EBITDA), Cholula (~$800M, 2020) plus FONA (flavors), and most recently a +25% stake in McCormick de Mexico bought from Grupo Herdez for $750M on 2026-01-02, taking ownership 50%→75% and triggering full consolidation (the source of the FY2025→Q1-FY2026 jumps in noncontrolling interest, $31.6M→$575.8M, and debt). This matters for two reasons: (1) it explains the ~$8.8B of goodwill + intangibles on a ~$5.8B-equity balance sheet (tangible common equity is negative); and (2) it establishes management’s identity as a serial acquirer — the trait that culminates in Project Apollo.

Verdict — Business Overview. A high-quality, market-leading flavor business with a genuinely strong branded Consumer franchise (the cash and margin engine) and a stickier-but-lower-margin B2B Flavor Solutions leg. Revenue quality is above-average for packaged food — consumable, habitual, low-ticket, repeat-purchase — but it is not a growth or subscription model; it is a branded, channel-anchored, mostly-mature consumables franchise whose reported growth has been price-led and whose corporate identity is serial acquisition.

3. Industry Dynamics

3.1 Structure of the spices/seasonings/flavor industry

The global spices-and-seasonings market is large (~$20B+ branded, growing low-to-mid single digits) and, at the branded end, concentrated around McCormick, which holds the #1 global position (management cites multiples of its nearest branded competitor’s size in many markets) and ~20%+ global branded share, with much higher shares in core US categories. The structure is favorable relative to most of packaged food: the category is infrequently purchased, low-ticket, and habitual, which historically conferred real pricing power and muted private-label substitution (a consumer will not switch a $4 spice they buy twice a year to save $0.80). McCormick’s scale in global sourcing (vanilla, pepper, garlic, capsicum, herbs) is a genuine cost advantage that underpins both its branded margins and its private-label supply.

The adjacent flavor-house industry (compound flavors, the Flavor Solutions battleground) is an oligopoly of Givaudan, IFF, Symrise, and Sensient — larger and more technically specialized in pure flavor chemistry than McCormick, which competes credibly in seasonings and blends but is a challenger in high-end flavor creation.

3.2 The two-sided private-label dynamic

McCormick is unusual: it is simultaneously the #1 branded spice seller and a leading private-label spice supplier to the same retailers. This is a hedge (it monetizes trade-down rather than only losing to it) but also a tell — it concedes that the branded moat does not fully prevent substitution at the margin, and private-label spice volumes have been gaining as consumers economize. The honest read: the two-sided position is a partial moat and a partial margin trap — it caps downside share loss but dilutes blended margin and signals that the category is more contestable on price than the “infrequent purchase” framing implies.

3.3 The demand debate — GLP-1, cook-at-home, and volume

Three secular questions hang over the category. (1) GLP-1 / weight-loss drugs: the bear fears structural calorie reduction. McCormick’s rebuttal — “we flavor calories while others compete for them” (i.e., flavor is a small, low-calorie input that makes healthier home cooking palatable) — is genuinely more defensible than for snacks or sugary beverages, and is corroborated by a 2025 volume inflection (see Growth). (2) Cook-at-home vs. dining-out: McCormick benefits from at-home cooking (Consumer) but its Flavor Solutions/foodservice leg benefits from dining-out — a partial natural hedge. (3) Packaged-food malaise: the broad center-store volume stagnation and the rotation of capital out of low-growth staples (the same force that has compressed the multiples across the packaged-food cohort) has dragged MKC’s multiple down with the cohort, arguably indiscriminately.

3.4 Marathon capital-cycle read

Verdict. Structurally good but maturing — and better than most of packaged food. Concentrated #1 branded leadership in an infrequent, low-ticket, habitual category with real (if narrowing) pricing power and a genuine global-sourcing cost scale. It is structurally superior to center-store CPG and more GLP-1-resilient than snacks/beverages. But it is not a growth industry: private-label migration, packaged-food volume malaise, and commodity/tariff cost volatility cap it, and the proposed combination pushes McCormick toward the more-challenged savory-condiment end (Knorr/Hellmann’s), not away from it.

4. Competitive Position

4.1 The moat — named, tied to financials, and bounded

Applying Greenwald’s framework (a real advantage must be supply/cost, demand captivity, or economies-of-scale-plus-captivity, and must show up as stable share + ROIC above cost of capital):

The branded demand-captivity moat in Consumer is real — it shows up directly in the ~6-point operating-margin premium of Consumer over Flavor Solutions, in 130+ years of brand equity, and in McCormick’s ability (until the 2022–23 elasticity episode) to push price through an infrequent purchase. The global-sourcing cost scale is the supporting supply advantage and is what lets McCormick profitably run both the branded and the private-label sides. But the moat is narrowing, not widening: gross margin remains ~3 points below its 2020 level (pricing did not fully recover inflation), volumes went flat-to-negative under price-led growth in 2022–24, private-label share has crept up, and consolidated ROIC has fallen to ~8.7% ≈ WACC — the unambiguous financial signal that the moat is protecting the business but no longer compounding it.

4.2 Head-to-head

• Branded spices/seasonings/condiments: McCormick is dominant and not commoditizing at the brand level; the credible competition is private label (Olde Thompson and retailer store brands) on price, and a long tail of regional brands. Kraft Heinz (Grey Poupon, A1), Unilever (Knorr — soon to be inside McCormick), and McCormick’s own private-label supply round out the field. Durable advantage — the franchise.
• Flavor Solutions / compound flavor: McCormick is a credible top-tier seasonings/blends player but a challenger versus Givaudan/IFF/Symrise/Sensient in pure flavor chemistry, which out-scale it in R&D. Good business, contestable position, no dominance.
• Versus the staples cohort: McCormick’s franchise quality (margin, share, category structure) is superior to KHC and most center-store CPG, comparable in brand strength to HSY in its niche, and its de-rating has been cohort-wide and arguably indiscriminate — it now trades far closer to broken-value names than its franchise merits.

4.3 What the deal does to the moat

Project Apollo dilutes the quality of the moat. McCormick would trade 100% of a focused, high-share, demand-captive spice franchise for 35% of a combined company in which Knorr and Hellmann’s — mature, scaled, but more private-label-exposed and slower-growing savory brands — become a large share of the portfolio. The combined B2B foodservice platform (~$6B sales) is genuinely scaled, and $600M of cost synergies are real if delivered. But the structural effect is to move McCormick down the quality curve toward the center-store malaise it currently sits above — the opposite of moat-widening capital allocation.

Verdict — A durable but NARROWING moat, being structurally diluted. Branded spices remain a genuine Greenwald demand-captivity + cost-scale moat (the crown jewel), validated by the segment-margin premium and decades of share. But ROIC ~= WACC says the moat is no longer compounding per share, private-label and elasticity are nibbling the edges, and the proposed combination trades focused franchise quality for scale and synergies in a more-contested category. The moat is real; it is not getting wider.

5. Growth History and Forward Opportunities

5.1 History — price-led, EPS-flat

The five-year record is the heart of the bear case: revenue grew ~4%/yr but diluted EPS went from $2.78 to $2.93 — flat. Three forces collided: (1) the 2021–22 inflation shock compressed gross margin from 41.1% to a 35.8% trough; (2) revenue growth was almost entirely price, with volumes flat-to-negative in 2022–24 as price increases triggered elasticity (consumers traded down to private label or smaller sizes); and (3) interest expense climbed (~$135M in 2020 to ~$196M gross by 2025) as the RB Foods/Cholula debt load met higher rates. The franchise’s quality simply did not convert into per-share earnings growth — and the multiple compressed to match.

5.2 The FY2025 volume inflection — real but fragile

The genuinely improving fact: FY2025 marked a return to volume-led growth. Management cited a “fifth consecutive quarter of volume-led growth” by Q3-FY2025; Consumer organic sales rose ~3% on almost-all-volume, the Americas +3% volume, EMEA +4% (+1 volume / +3 price). This supports the bull view that the 2022–24 volume weakness was a cyclical elasticity/destocking episode (overlapping the inflation price-push), not a secular private-label/GLP-1 collapse. The fragility: Flavor Solutions organic was only ~+1% (flat volume), China foodservice/high-end dining is soft, and a new round of tariff-driven pricing in late-2025/2026 reintroduces elasticity risk just as the volume recovery is establishing itself.

5.3 Forward drivers and the deal’s distortion

McCormick’s standalone forward algorithm is modest: ~2–3% organic sales growth (Foley explicitly frames the combined entity’s organic base as “2–3%,” with the lift to “3–5%” coming from deal self-help, not industry recovery), partial gross-margin recovery via the CCI (Comprehensive Continuous Improvement) and GOE cost programs, and bolt-on M&A. The FY2026 guide is the cleanest illustration of the distortion: reported sales +13–17% but organic only +1–3% — virtually all the headline growth is the de Mexico consolidation, with adjusted EPS guided to just $3.05–$3.13 (+2–5%). The real forward growth engine, if the deal closes, is the $600M of synergies and the scaled B2B platform — i.e., the growth case has been outsourced to the merger.

Verdict — Low-quality history, fragile-but-genuine recent inflection, deal-dependent forward. Five years of flat EPS is the franchise’s indictment; the FY2025 volume return is a real positive that argues the volume weakness was cyclical, not structural. But standalone organic growth is a ~2–3% story, the FY2026 headline is an acquisition mirage, and management’s own framing concedes the meaningful growth uplift depends on synergies from a deal that won’t close until mid-2027. Treat the mid-single-digit “algorithm” as deal-contingent, not standalone.

6. Financial Quality

6.1 The gross-margin bridge and operating leverage

The single most important standalone financial question is whether the gross margin recovers. The bridge: 41.1% (2020) → 35.8% trough (2022) → 38.5% (2024) → 37.9% (2025). Three years of CCI cost savings and pricing recovered roughly two of the ~5 points lost to inflation — and FY2025 actually slipped backward (38.5%→37.9%) on mix and reinvestment of pricing into brand marketing/volume. A return to 40%+ is an open question, not a base case. The CCI/GOE programs are real and quantified (hundreds of millions in cumulative savings), and they are what kept operating margin from collapsing further, but they are running into commodity/tariff re-inflation. Operating leverage is modest: a mature, ~2–3%-organic-growth business does not generate much incremental margin without the cost program doing the work.

6.2 Quality of earnings — clean, with one large optical distortion

McCormick’s earnings quality is clean relative to its cohort. The GAAP-vs-adjusted gap is small and legitimate: FY2025 GAAP diluted EPS $2.93 vs adjusted ~$3.00; FY2024 $2.92 vs $2.95 — the add-backs (GOE restructuring, transaction/integration, inventory step-ups) are modest, unlike the serial “special charges” that inflate KHC/HSY adjusted numbers. Cash conversion is good: FY2025 operating cash flow ~$962M, capex ~$222M → real FCF ~$740M, OCF/NI ~1.22x — net income is backed by cash, not divergent from it.

The one big distortion is optical and well-understood: Q1-FY2026 GAAP diluted EPS of $3.77 (versus $0.60 a year prior) is ~83% a non-cash $866.8M remeasurement gain from marking the previously-held 50% de Mexico stake to fair value upon gaining control. Adjusted Q1 EPS was $0.66 (+10%); organic sales +1.2%. The GAAP $3.77 must be discarded entirely — it is the mirror image of a one-time gain, not earning power.

6.3 Returns on capital — the franchise is not compounding

Consolidated ROIC ~8.7% sits essentially at the cost of capital — a damning figure for a portfolio of premium brands. The cause is the ~$8.8B of goodwill + intangibles from RB Foods/Cholula sitting in the denominator: the underlying Consumer franchise earns high returns on tangible capital, but the price paid to assemble the portfolio (RB Foods at ~20x EBITDA) means the blended return barely clears WACC. This is the financial signature of “great brands, mediocre acquisition prices” — and it is precisely why the EPS line has been flat despite revenue growth.

6.4 Balance sheet — investment-grade now, re-levering soon

Pre-deal, the balance sheet is sound: FY2025 net debt ~$3.9B, net-debt/EBITDA ~2.95x (down from ~3.6x post-Cholula — three years of genuine deleveraging), investment-grade, current ratio 0.70 (normal for a staple with supplier terms). Tangible common equity is negative (~−$3B) because $8.8B of intangibles exceed $5.8B of book equity — so P/B is not a meaningful floor (a recurring feature of serial brand-acquirers). The crucial forward point: Project Apollo reverses the deleveraging, taking net leverage to ~4x at close (the $15.7B bridge + $2B term loan funding the cash to Unilever), with a stated path back to ~3x within two years and a commitment to defend the investment-grade rating.

Verdict — Financial Quality: MODERATE. Earnings quality is clean (small, legitimate adjustments; OCF > NI; ~$740M real FCF), the gross-margin recovery is partial and stalling, and — decisively — consolidated ROIC ~= WACC means the franchise’s quality is not translating into per-share value creation. Anchor valuation to adjusted EPS (~$3.00) and through-cycle FCF (~$700–750M), discard the Q1 GAAP $3.77, and weight the re-levering-to-4x deal risk heavily — the balance-sheet strength that has long differentiated McCormick is about to be spent.

7. Capital Allocation

7.1 The M&A record — serial lever-up/de-lever, now culminating

McCormick’s capital-allocation identity is serial acquisition financed with debt, then deleveraging, then repeat:

The pattern is Marathon’s asset-growth anomaly in motion: RB Foods at ~20x EBITDA did not clearly earn its cost of capital (consolidated ROIC fell to ~WACC and EPS went flat), and the team is now proposing to roughly double the company again — issuing equity at a decade-trough multiple — to absorb a larger, lower-growth, more-private-label-exposed savory-foods business. Whether Apollo’s $600M synergies redeem the math is the entire debate; the track record says be skeptical of a serial acquirer’s accretion claims.

7.2 Dividend and buyback

The dividend is the franchise’s pride: 40 consecutive annual increases (a Dividend Aristocrat; 102-year payment history), DPS $1.24 (2020) → $1.80 (2025), a ~61% payout, and a ~4.0% yield at $46.64. It is covered ~1.5x by FCF and is safe near-term, though the high-and-rising payout plus the deal’s 4x leverage likely caps dividend growth for a few years. The buyback is effectively suspended — only ~$35M/yr spent against a $414M-remaining authorization, with the cash directed to deleveraging; shares have been flat at ~268M. The deal’s stock consideration will increase the share count substantially. So the per-share compounding tools (buyback, EPS growth) are both dormant, leaving the dividend as the sole near-term return vehicle.

7.3 Governance, incentives, and insiders

• Dual-class control. McCormick has voting (MKC.V) and non-voting (MKC) shares; the voting class is tightly held (non-affiliate voting float is worth only ~$1.1B versus ~$18B of non-voting), so the family/insiders effectively control the shareholder vote. This is decisive for Project Apollo: the required McCormick shareholder approval is far more controllable than for a single-class company, and it structurally limits the activist’s leverage over the outcome.
• The incentive-metric flaw (governor problem). The comp plan rewards adjusted-EPS, net-sales, volume, and operating-income growth, plus a long-term cumulative-net-sales plan with a relative-TSR modifier — but there is no return-on-capital (ROIC/economic-profit) metric. For a sub-10%-ROIC serial acquirer, this is exactly the wrong design: it pays management to get bigger, not to earn high returns on the capital deployed — the incentive root of the empire-building. (Mitigants: a volume metric was added in FY2024, and the relative-TSR modifier is present.)
• Insiders. Across the trailing window there was one open-market purchase (director Hattersley, 2,000 shares @ ~$52.98, ~$106K) and zero open-market buying by the CEO (Foley) or CFO (Gabriel) — only routine phantom-stock grants and tiny dividend-reinvestment entries. No insider conviction signal.

Verdict — Capital Allocation: MEDIOCRE, and now high-stakes. A serial acquirer with a portfolio of genuinely great brands bought at prices that dragged consolidated ROIC to ~WACC, an incentive plan with no return-on-capital metric, a suspended buyback, and — now — a transformational RMT that re-levers to 4x and dilutes holders to 35%, proposed at a trough valuation. The dividend record is exemplary and the deleveraging discipline (3.6x→2.95x) was real; both are about to be tested. This is the weakest pillar of the thesis.

8. Changes and Headwinds — Last Two Years

The transformational change — Project Apollo (2026-03-31). McCormick agreed to combine with Unilever’s Foods business (Knorr, Hellmann’s, Maille) in a Reverse Morris Trust: 65% Unilever / 35% McCormick pro-forma ownership, $15.7B cash to Unilever (financed by a $15.7B bridge + $2B term loan), both struck at ~13.8x CY2025 EBITDA, $600M run-rate synergies (~⅔ by end of year 2, full by year 3), net leverage ~4x→~3x within two years, a combined ~$6B B2B foodservice platform, a secondary European listing, and a mid-2027 close subject to McCormick shareholder vote and regulatory clearance. Management claims accretion to growth, adjusted operating margin, and adjusted EPS in the first full year — but declined to quantify the EPS accretion (“not putting a number there”), and framed the growth uplift to “3–5%” as deal self-help, conceding the combined organic base is only “2–3%.” Contradiction flag (management commentary treated as hypothesis): management presents the deal as value-creating, yet the market marked the stock down after the announcement and a marquee long-term Unilever holder (Terry Smith / Fundsmith) publicly exited Unilever criticizing the structure and McCormick’s “management and returns.”

Other changes: the de Mexico consolidation (Jan 2026, +$750M, →75%) — accretive to scale, optically inflating FY26 reported growth; the 40th consecutive dividend increase (Jan 2026); a genuine FY2025 volume-led growth inflection (five consecutive quarters); and continued CCI cost-program delivery.

Headwinds/overhangs: (1) the deal overhang itself — dilution to 35%, 4x leverage, a long mid-2027 timeline, cross-border antitrust (Europe the real risk, given the Knorr/mayo overlap; US “adjacent”), and $17.7B of financing to execute; (2) volume fragility — the recovery leans on lapping easy comps, with fresh tariff pricing reintroducing elasticity; (3) China foodservice softness; (4) private-label trade-down and packaged-food malaise dragging the cohort multiple; (5) commodity/tariff cost re-inflation threatening the gross-margin recovery; and (6) the activist wildcard — Toms Capital’s stake (~6/1/26) with undisclosed demands, constrained by the dual-class vote.

Verdict — On balance, the changes WEAKEN the standalone thesis even as they raise the stakes. The genuine positive (volume inflection) is overwhelmed by a transformational, dilutive, re-levering deal that the market and a sophisticated holder have judged skeptically. The next two years are now governed by a binary, long-dated merger rather than by the franchise’s own cash-generative steadiness.

9. Risk Analysis

Likelihood and Impact each Low/Med/High over a ~12–24 month horizon; “Impact” = effect on intrinsic value / the thesis.

Risk-matrix summary. The high-impact quadrant is dominated by #1 (deal value-destruction) and #2 (structural volume decline) — and they are partly independent (the deal could be a poor trade even if volume recovers; volume could collapse even if the deal is shelved), which is what makes the situation genuinely two-sided. Catastrophic loss is not a realistic scenario: this is a profitable, cash-generative, IG-rated market leader with a 40-year dividend; the realistic downside is a value de-rate (a botched deal at 4x leverage, the KHC path) rather than impairment of capital. The aggregate risk is concentrated in management’s capital-allocation choice, not in the franchise’s solvency.

10. Valuation Discussion — Embedded Expectations

No price target, no recommendation. Embedded-expectations and scenario framing only. Multiples on adjusted earnings; the Q1 GAAP $3.77 is discarded.

10.1 Live recompute and the standalone multiples

At $46.64 (2026-06-18), ~268.4M shares → market cap ~$12.5B. Adding pre-deal net debt ~$3.9B (plus the ~$0.58B de Mexico minority) → live EV ~$16.8B. (ROIC’s screen EV uses a stale ~$67–71 price basis — discard it.) The honest standalone multiples:

10.2 Own-history and comps — decade-cheap, not yet broken-value

On its own history, today’s ~12.1–12.5x EV/EBITDA is below the entire prior 11-year range (prior trough ~16.8x; 2019–22 mostly 22–25x), and ~15.5x P/E sits against a history overwhelmingly 22–33x — bottom-decile, the cheapest McCormick in a decade. (Note: the an own-history valuation-percentile feed was glitched for MKC — it reported a TTM EPS of ~$6.10, double the true ~$3.00, and identical 0.338 percentiles across P/E/P/B/P/S, a fallback artifact; the decade-cheap read is computed independently from the ROIC multiple series.) Against the cohort, MKC at ~12x EV/EBITDA sits above broken-value names (KHC ~7.8x, INGR ~6.8x) and below premium franchises (HSY ~21x, MDLZ ~18.3x) — it has re-rated toward value but is not priced as a broken KHC. The franchise quality (18.6% Consumer margin, 40-year dividend, #1 share) argues it is mispriced toward the low end of where its quality belongs.

10.3 Embedded expectations — the price underwrites permanent stagnation

A reverse-DCF on ~$46.64 implies only ~1.5–2.5% perpetual FCF growth — below MKC’s own ~4% revenue CAGR and below the ~2–3% standalone organic algorithm. In other words, the standalone price embeds permanent volume stagnation, no gross-margin recovery, and no re-rating. If the FY2025 volume inflection proves that the 2022–24 weakness was cyclical (elasticity + destocking) rather than secular (private-label + GLP-1), the standalone franchise is worth more than spot. The countervailing fact keeping it “fair” rather than “screaming cheap” is ROIC ~= WACC: a business that earns only its cost of capital does not deserve a premium multiple, decade-cheap or not.

10.4 The deal lens — accretive on paper, value-ambiguous in the tape

The deal is struck at ~13.8x for both sides, so the exchange is “fair” in like-for-like EBITDA terms; the accretion comes entirely from the $600M synergies (~$468M after-tax, capitalized at ~12–16x ≈ ~$5.6–7.5B, of which MKC’s 35% ≈ ~$7–10/share of synergy value) plus any re-rating of the combined entity. At strike, McCormick was marked at ~$21B equity ≈ ~$78/share. The stock trades ~40% below that and kept falling after 3/31/26 — the market is not pricing a clean +$78 mark. It is discounting (a) deal-break/execution risk and (b) the structural downgrade from a focused ~12x-net-debt spice pure-play to 35% of a 4x-levered ~$60B conglomerate carrying mature Knorr/Hellmann’s volumes. The deal is itself a re-classification/de-rating event — even if it closes, the combined entity may earn a lower (conglomerate) multiple than standalone McCormick once did.

10.5 Scenarios (per-share zones; NOT price targets)

The asymmetry. At ~$46.64 the tape prices something worse than both the standalone base and the deal-at-strike mark. Both deal-success and deal-break can plausibly resolve higher than spot; the genuine downside requires the conjunction of structural volume decline and a value-destructive close at 4x leverage. The reward/risk is skewed slightly favorable at this price — the unusual feature of a name the market has decided to dislike on both its standalone and its deal merits simultaneously.

Verdict. Stripped of the GAAP distortion, McCormick trades at a decade-low ~15.5x adjusted EPS / ~12x EV/EBITDA / ~4% yield — fair-leaning-cheap for a wide-moat aristocrat whose only honest knock is ROIC≈WACC. The price embeds permanent stagnation, which is too pessimistic on the franchise but defensible on the returns. Overlaid is a transformational deal struck at parity, accretive only via synergies, that the market has judged a re-rating event — leaving the stock priced below both its standalone and its deal-struck values, with a slightly favorable, if event-driven, asymmetry.

11. Variant Perception

Consensus has settled into a two-part bearish-to-neutral view: (1) McCormick is a structurally challenged low-growth staple (flat EPS for five years, private-label and GLP-1 pressure, packaged-food malaise) that deserves its de-rating; and (2) the Unilever deal is a value-ambiguous-to-destructive empire-building move that dilutes holders to 35%, re-levers to 4x, and bolts on a mature, slower-growth savory-foods unit — a verdict reinforced by the stock falling after the announcement and by Terry Smith’s public exit from Unilever. The single positive datum the bulls hold is the arrival of an activist (Toms Capital) and the decade-cheap multiple.

The strongest bull case: a genuine, durable, #1-global demand-captivity spice moat (~6-point Consumer margin premium, 40-year dividend) trading at its cheapest multiple in a decade and ~51% off its peak; a confirmed FY2025 volume inflection arguing the 2022–24 weakness was cyclical, not secular; a more-GLP-1-resilient category than snacks/beverages (“flavor the calories”); a safe ~4% aristocrat yield underpinning the price; an event-driven activist who may force a better deal or a return to a pure-play-plus-buyback path; and $600M of real synergies if the deal closes. “An abandoned, wide-moat spice champion at a decade-cheap multiple, with optionality on either a sweetened deal or a volume-led standalone re-rating.”

The strongest bear case: a serial acquirer earning only its cost of capital (ROIC ~8.7%), with five years of flat EPS, using a trough valuation as currency to issue away 65% of the company and re-lever to 4x to absorb mature, private-label-exposed Knorr/Hellmann’s — an incentive plan with no return-on-capital metric paying management to do exactly this; a fragile volume “recovery” leaning on easy comps just as tariff pricing reignites elasticity; and a long-dated, cross-border, antitrust-exposed deal that the market and a marquee holder have already panned. “A no-growth, sub-WACC serial acquirer diluting and re-levering itself at the bottom — the KHC path, dressed as a flavor leader.”

The variant view (where consensus may be offsides): the market has collapsed two separable judgments into one undifferentiated discount. It is pricing the standalone franchise as a permanently-stagnant value trap and the deal as a near-certain value-destroyer simultaneously — and at ~$46.64 the stock sits below both the standalone base case (~$50–62) and the deal-at-strike mark (~$78). The factor read corroborates an over-discount: beta 0.196, deeply negative Sharpe across every horizon, LowVol +0.36 / DividendYield +0.11 / Growth −0.44 loadings, momentum zeroed — this is an abandoned-value, low-volatility, rate-sensitive defensive staple in a multi-year grind, not a high-beta falling knife (it bleeds, it does not crash). Consensus is most likely wrong in underweighting two independent positive resolutions: (a) a standalone volume-led re-rating if the FY2025 inflection holds, and (b) an activist-or-board-forced improvement to deal terms (the dual-class vote cuts both ways — it lets the family push the deal through, but it also lets the board withdraw it for a buyback/pure-play if the math is challenged). The honest two-sided conclusion: the bear is right that capital allocation is the weak pillar and the deal is a genuine risk; the bull is right that the price now embeds both a value-trap standalone and a value-destructive deal, neither of which is established — an over-determined discount on a real franchise.

The single most important monitorable: the deal’s progression and terms — any sign of (a) a quantified EPS-accretion disclosure, a collar, or sweetened terms; (b) an activist 13D/letter from Toms Capital and the board’s response; © regulatory milestones (EU antitrust on the Knorr/mayo overlap); or (d) a withdrawal in favor of buybacks/pure-play. Secondary monitorable: the standalone organic volume trend (the Q2-FY2026 print on 2026-06-25 and beyond) — the cleanest test of whether the FY2025 recovery is durable or was an easy-comp mirage.

12. Fact vs. Interpretation Table

13. Open Questions

1. Deal terms and EPS accretion. Will management quantify the adjusted-EPS accretion, and what is the post-synergy per-share value of MKC holders’ 35% stake versus standalone value? Is there a collar or any downside protection for MKC holders on the fixed share count?
2. Toms Capital’s thesis. What does the activist actually want — capital discipline/quantified accretion, a sweetened ratio, governance changes, or withdrawal in favor of a pure-play-plus-buyback? Watch for a 13D/letter. How binding is the family-controlled dual-class vote against any of these?
3. Volume durability. Is the FY2025 volume inflection structural (cyclical weakness over) or an easy-comp mirage that fresh 2026 tariff pricing will reverse? The Q2-FY2026 print (2026-06-25) and subsequent quarters are the test.
4. Gross-margin path. Can CCI/GOE plus pricing recover gross margin back toward 40%, or does tariff/commodity re-inflation cap it near ~38%?
5. Regulatory. What is the EU antitrust exposure on the Knorr/Hellmann’s-vs-McCormick-condiment/mayo overlap, and does the mid-2027 timeline hold?
6. Leverage and the rating. Does the path from ~4x to ~3x within two years (and IG defense) survive an integration stumble or a synergy shortfall?

14. What Must Be True (Bull and Bear, with Falsification Tests)

Bull case — what must be true

1. The standalone franchise is mispriced toward value-trap levels it doesn’t merit, and either a volume-led re-rating or improved deal terms closes the gap. Falsifies the bull if: organic volume rolls back negative in the next two prints (proving private-label/GLP-1 are structural, not cyclical), with no sign of deal improvement.
2. The deal is either improved for MKC holders or not value-destructive — synergies are quantified into real EPS accretion, or the board/activist forces better terms or a pure-play pivot. Falsifies the bull if: the deal closes on the announced terms with no quantified accretion, integration slips, and leverage stays stuck near 4x.
3. The ~4% dividend and decade-cheap multiple provide a floor while the situation resolves. Falsifies the bull if: the dividend growth is suspended (not just slowed) to defend the rating, signaling balance-sheet stress.

Bear case — what must be true

1. This is a sub-WACC serial acquirer destroying per-share value by diluting and re-levering at the bottom — the KHC path. Falsifies the bear if: consolidated ROIC inflects above WACC, the volume recovery proves durable, and the combined entity is demonstrably accretive at corporate-average returns.
2. The volume “recovery” is an easy-comp mirage masking secular private-label/GLP-1 erosion. Falsifies the bear if: McCormick posts multiple quarters of positive volume-led organic growth through a normal (non-easy-comp) period, with private-label share stabilizing.
3. The deal closes at a conglomerate multiple with integration drag, leaving holders with 35% of a 4x-levered, lower-multiple business. Falsifies the bear if: the deal is withdrawn or repriced in MKC holders’ favor, or the combined entity sustains a premium multiple post-close.

15. Source Appendix

The full source list is maintained in the separate Source Appendix (Appendix B of the combined report). Primary sources include: McCormick FY2021–FY2025 10-Ks (EDGAR, CIK 0000063754), the Q1-FY2026 10-Q, the FY2025 and Q1-FY2026 earnings 8-Ks (EX-99.1 press releases), the Project Apollo deal filings (the 2026-05-01 Term Loan/Bridge 8-K, the 2026-04-01 Rule-425 investor-call and transaction-overview communications, referencing the Merger Agreement dated 2026-03-31), the DEF 14A proxy, Form 4 insider filings, and EDGAR XBRL companyfacts; the ROIC.ai financial database (statements, ratios, EV, multiples) and earnings-call transcripts (Q3-FY25, Q4-FY25, Q1-FY26); the FactorsToday factor model (loadings, leaderboard, factor-similar peers); price history and news feeds; public filings and market data for the packaged-food peer set (HSY, KHC, MDLZ, KDP, KO, PEP, CL, INGR) for cohort framing; and public press on the Toms Capital stake and the Fundsmith/Unilever exit. Each is cited with access date 2026-06-21. Management commentary is treated throughout as hypothesis and validated against filings, financials, and external evidence.

The analysis in this article carries no investment recommendation and no price target; the Author’s Take block is a separately-labeled subjective view. This is general information, not investment advice.

APPENDIX A — Standard Diligence Questionnaire

Answers grounded in the underlying research; Fact / Interpretation / Assumption labels applied where it matters. Greenwald (Competition Demystified) and Marathon (Capital Returns) frameworks applied where they add insight. Report date: 2026-06-21.

General

What thoughtful questions have other investors asked about this company? The debate clusters around five themes: (1) Is the volume weakness cyclical or secular? — five years of flat EPS and flat-to-negative volumes 2022–24 versus a genuine FY2025 volume-led inflection; bulls say elasticity/destocking is over, bears say private-label/GLP-1 erosion is structural. (2) Is the Unilever Foods deal value-creating or value-destroying? — diluting MKC holders to 35%, re-levering to 4x, and absorbing mature Knorr/Hellmann’s, with accretion resting entirely on $600M of synergies management declined to quantify into EPS. (3) Will the gross margin recover toward 40%, or is it capped near 38% by tariffs/commodities? (4) Did the serial M&A (RB Foods at ~20x) ever earn its cost of capital given consolidated ROIC ~8.7% ≈ WACC? (5) What does the activist (Toms Capital) want, and can the dual-class family vote override it? On the Q1-FY2026 call the sell-side focused on synergy phasing, leverage/IG defense, the EU antitrust path, and the organic-vs-reported growth gap — precisely the load-bearing assumptions in our variant view.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? (Interpretation) Roughly mid-cycle, with a depressed multiple rather than depressed earnings. Adjusted EPS (~$3.00) is near a five-year high in absolute terms but has been flat for five years; the gross margin (37.9%) is ~3 points below its 2020 level (a cyclical low on margin, not a high). The multiple, not the earnings, is at a cyclical trough (decade-low ~15.5x). So earnings are mid-cycle; valuation is cyclically low.

Driven by the external environment or internal actions? (Interpretation) Both. External: input-cost inflation (2021–22) and deflation/recovery (2024), consumer trade-down, GLP-1 sentiment, and rates (which de-rated the bond-proxy multiple). Internal: the CCI/GOE cost programs (margin defense), the price-led growth strategy (which triggered elasticity), and the serial-acquisition capital allocation (which drove the interest drag and the ROIC≈WACC outcome). The deal is a purely internal strategic choice.

How stable are revenues? (Fact) Very stable in demand, lumpy in reported growth from acquisitions/FX. Spices are consumable, low-ticket, habitual repeat purchases — among the most defensive demand profiles in food (beta 0.196). Reported revenue, however, is distorted by M&A (the de Mexico consolidation adds ~11–13 points to FY2026 reported growth on ~1–3% organic) and FX.

Outlook for products/services? (Fact, mgmt = hypothesis) Standalone organic ~2–3%; management’s “3–5%” combined-company target is explicitly deal self-help (synergies), not industry recovery. FY2026 adjusted EPS guide $3.05–$3.13 (+2–5%).

How big will this market be — growing, shrinking, domestic or international? (Fact) The branded global spice/seasoning market is large (~$20B+) and growing low-to-mid single digits; flavors (Flavor Solutions’ arena) grow mid-single-digits. McCormick is ~61% US / ~39% international, #1 globally in branded spices. The markets grow slowly; the company’s challenge is share-of-a-mature-pie economics, not a shrinking TAM.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? (Interpretation) More, at the margin. Branded spices remain a supply-disciplined oligopoly (no new branded entrants), but private-label spice supply (the marginal new capacity) is gaining share on price, and Flavor Solutions faces larger, better-resourced flavor houses (Givaudan/IFF/Symrise). The deal pushes McCormick toward the more-competitive savory-condiment end.

How profitable is the business (ROIC, ROE)? (Fact, computed) Consolidated ROIC ~8.7% ≈ WACC, ROE ~14%, operating margin 16.0% (Consumer 18.6% / Flavor Solutions 12.4%). The underlying Consumer franchise earns high returns on tangible capital; the ~$8.8B of acquired goodwill/intangibles drags the blended return to ~WACC — the core financial tell that the moat protects but does not compound.

How profitable is the industry — how many competitors, what barriers to entry? (Fact/Interpretation) Branded spices: a concentrated structure (McCormick #1 globally) with a real brand/distribution/sourcing barrier — the most profitable tier (Consumer ~18.6% margin). Flavor Solutions: more competitors (Givaudan, IFF, Symrise, Sensient), scale/R&D-based, low-teens margins. Private label: low barriers, value-migrating.

Can the business be easily understood? (Interpretation) Yes — it makes and sells flavor (branded retail + B2B). The complexity is in the deal (an RMT with Unilever) and in normalizing the de Mexico consolidation and the price-vs-volume decomposition, not in the base model.

Can it be undermined by foreign low-cost labor? (Interpretation) Limited. The moat is brand/distribution/sourcing-scale, not domestic manufacturing cost; private label (often lower-cost-supplied, including by McCormick itself) is the real low-cost threat, and it is a known, partially-hedged dynamic rather than an offshore-labor disruption.

Do brands matter? (Fact) Yes, decisively in Consumer. McCormick, French’s, Frank’s RedHot, Cholula, OLD BAY are default, habitual, trusted choices in an infrequent, low-ticket purchase — the source of the ~6-point Consumer margin premium. Brand matters far less in private label and in commodity Flavor Solutions inputs.

What is the nature of competition? (Interpretation) Brand-habit + shelf/category-captaincy + sourcing scale in Consumer; price in private label; technical formulation + customer-intimacy + scale in Flavor Solutions.

Customers’ switching costs? (Fact) Nil at the consumer level (a $4 jar, no lock-in) — the moat is getting chosen by habit, not switching costs. In Flavor Solutions, switching costs are real but moderate (embedded co-developed formulas, qualification), contestable by larger flavor houses.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? (Interpretation) Yes — the #1-global brand equity and category-captain shelf relationships are unbooked intangibles far exceeding their accounting carrying value’s economic worth. Offsetting: the ~$8.8B of booked goodwill/intangibles from RB Foods/Cholula is arguably over-stated relative to the sub-WACC returns it generates.

Off-balance-sheet liabilities? (Fact/Open Question) The principal forward liability is the deal financing — a $15.7B bridge + $2B term loan that will move net leverage to ~4x at close (currently a commitment, not on-balance-sheet until close). Standard operating leases, pension, and contingencies are disclosed and modest.

How conservative is the accounting? (Interpretation) Leans conservative/clean. The GAAP-vs-adjusted gap is small and legitimate (unlike KHC/HSY); OCF exceeds NI (1.22x); the one big optical item (Q1-FY26 GAAP $3.77) is a transparent non-cash de Mexico remeasurement gain, clearly disclosed and easily normalized out.

How CapEx-hungry is the business? (Fact) Light — capex ~$222M, ~3.2% of sales; a brand/sourcing business, not capital-intensive. FCF conversion is strong (~$740M real FCF, OCF/NI 1.22x).

Capital Allocation & Management

How much FCF does the business generate, how does management use it, what is the philosophy? (Fact) Real FCF ~$740M FY2025 (OCF ~$962M − capex ~$222M). Uses: dividend (~$483M, the priority) + deleveraging; buyback suspended (~$35M); periodic debt-funded M&A. Philosophy: protect the IG rating, grow the dividend every year, reinvest in cost programs/brands, and acquire for scale. (Interpretation: reasonable on the dividend/deleveraging; the M&A record — RB Foods at ~20x, now the Unilever RMT — is where the philosophy has destroyed or risked per-share value.)

Significant acquisitions recently? (Fact) Yes — McCormick de Mexico +25% ($750M, Jan 2026, →75% control), and the transformational Unilever Foods RMT (announced Mar 2026, close ~mid-2027). Prior: RB Foods $4.2B (2017), Cholula $800M + FONA (2020).

Buying back shares? (Fact) No, effectively suspended (~$35M/yr vs a $414M-remaining authorization; cash directed to deleveraging). Shares flat ~268M. The deal will increase the share count via stock consideration.

Issuing large amounts of new shares to insiders? (Fact) No — routine equity comp only. The deal, however, issues a large fixed block of stock to Unilever shareholders (the RMT consideration), diluting existing holders to 35%.

Compensation policy of directors/management? (Fact) Heavily incentive-based on adjusted-EPS / net-sales / volume / operating-income growth + a long-term cumulative-net-sales plan with a relative-TSR modifier. No ROIC/return-on-capital metric — the governor problem for a sub-WACC serial acquirer (rewards size over capital efficiency). A volume metric was added in FY2024 (a mild positive).

Motivations of management? (Interpretation) Long-tenured, founder-heritage company (CEO Brendan Foley, Chairman/President/CEO) with a dual-class structure that gives the family/insiders voting control. Aligned to the dividend and to the company’s scale/longevity; the incentive design and the Apollo deal both reveal a builder’s bias toward size, not per-share return. The dual-class control is the key governance fact: it lets the board push the deal through or withdraw it largely independent of public (non-voting) holders.

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? (Fact) No — a US C-corporation (Maryland), NYSE-listed, standard Form 1099. Note the dual share-class structure: voting MKC.V and non-voting MKC (the liquid listing). A secondary European listing is planned as part of the Unilever deal.

Dividend policy? (Fact) 40 consecutive annual increases (Dividend Aristocrat; 102-year payment history); DPS ~$1.84 run-rate, ~61% payout, ~4.0% yield; covered ~1.5x by FCF — safe near-term, with growth likely slowed (not cut) by the deal’s leverage.

How profitable is the business? (Fact) Gross margin ~38% (recovering, ~3pts below 2020), operating margin 16.0%, Consumer 18.6% / Flavor Solutions 12.4%, ROIC ~8.7% ≈ WACC, real FCF margin ~11%.

Is net income diverging from cash from operations? (Fact) No adverse divergence — OCF exceeds NI (1.22x), a quality signal. The Q1-FY26 nuance is the opposite of a red flag: GAAP NI was inflated by a non-cash $866.8M remeasurement gain; adjusted EPS ($0.66) and cash flow are the clean reads.

Risks & Downside

What factors would cause the stock to decline? (Interpretation) In order of likelihood × impact: (1) the deal proving value-destructive (dilution + 4x leverage + synergy shortfall); (2) organic volume rolling back negative (structural private-label/GLP-1 erosion); (3) gross-margin recovery stalling on tariffs/commodities; (4) deal regulatory/financing/closing problems; (5) a persistent cohort-wide staples de-rating. The deal-risk and volume-risk are partly independent, which is what makes the downside non-correlated and the situation two-sided.

Risk of a catastrophic loss? (Interpretation) Low. A profitable, cash-generative, IG-rated #1 market leader with a 40-year dividend and a deeply defensive demand profile (beta 0.2). The realistic downside is a valuation de-rate (a botched deal at 4x leverage — the KHC path, ~$38–44) rather than capital impairment. The 4x post-deal leverage is the one feature that raises the tail-risk above a typical staple, but IG and ~$740M FCF provide a wide cushion.

Chance of a total loss? (Interpretation) Negligible — not a realistic scenario for a cash-generative aristocrat with a fortress demand base. The risk is overpaying for a value-destructive transaction, not insolvency.

Recent News & Events

Has the business environment changed recently? (Fact) Yes — dramatically: (1) the Unilever Foods “Project Apollo” RMT announced 2026-03-31 (65/35, $15.7B cash, $600M synergies, mid-2027 close) — the dominant event; (2) the de Mexico consolidation (Jan 2026, $750M, →75%); (3) a Toms Capital activist stake (~6/1/26, demands undisclosed); (4) Fundsmith/Terry Smith’s public exit from Unilever (~5/27/26) criticizing the deal; (5) a UBS “tough setup” packaged-food note (6/2/26) and a “steep slump” valuation piece (6/3/26); (6) the 40th consecutive dividend increase (Jan 2026). Q2-FY2026 earnings land 2026-06-25.

Significant acquisitions? (Fact) The Unilever Foods combination (pending) and McCormick de Mexico +25% (closed Jan 2026).

Change in accounting policies? (Fact) No material policy change. The de Mexico step-acquisition triggered fair-value remeasurement (the Q1-FY26 $866.8M non-cash gain) and full consolidation — a consolidation/accounting event, not a policy change.

Recent changes — new markets, facilities, management? (Fact) No CEO/CFO change (Foley/Gabriel continuity). The transformational change is strategic — the pending combination with Unilever Foods, a planned secondary European listing, and the integration build-out — alongside the de Mexico consolidation.

APPENDIX B — Source Appendix

Sources supporting the research memo and diligence appendix. Primary sources prioritized over secondary. All web/market data accessed 2026-06-21 unless noted. Management commentary treated as hypothesis and validated against filings and external evidence.

A. Primary — SEC filings (EDGAR, CIK 0000063754)

1. Form 10-K, FY2025 — fiscal year ended 2025-11-30. Principal source: Item 1 (Business — two segments, brand portfolio, competition, customers, sourcing); Item 7 (MD&A — net-sales-by-segment, gross-margin bridge, CCI/GOE cost programs, adjusted-EPS reconciliation); segment footnote (Consumer $3,950.3M / 57.8% sales / ~67% op profit / 18.6% margin; Flavor Solutions $2,890.0M / 42.2% / 12.4%); debt and dividend notes; customer concentration (Walmart ~12%, PepsiCo ~12%; top-3 FS customers ~49% of FS sales).
2. Form 10-K, FY2021–FY2024 — used for the five-year revenue/margin/EPS history, the gross-margin bridge (41.1% 2020 → 35.8% 2022 trough → 38.5% 2024 → 37.9% 2025), and the RB Foods/Cholula goodwill and debt history.
3. Form 10-Q, Q1-FY2026 — quarter ended 2026-02-28. The McCormick de Mexico step-acquisition (50%→75%), the $866.8M non-cash remeasurement gain, GAAP diluted EPS $3.77 vs adjusted $0.66, organic sales +1.2%, the noncontrolling-interest ($31.6M→$575.8M) and debt ($4.16B→$4.92B) changes.
4. Form 8-K, 2026-03-31 (EX-99.1) — “McCormick Reports Strong First Quarter Performance and Reaffirms 2026 Outlook” — Q1-FY2026 results, FY2026 guide (reported sales +13–17%, organic +1–3%, adjusted EPS $3.05–$3.13).
5. Form 8-K, 2026-05-01 (“apollo-8k,” event date 2026-04-28) — Item 1.01 entry into the $2.0B Term Loan Agreement (Citibank, admin agent) and the $15.7B 364-day Bridge Facility commitment (Citigroup, Goldman Sachs, Morgan Stanley), financing the cash consideration for the pending combination with the foods business of Unilever PLC pursuant to the Merger Agreement dated 2026-03-31.
6. Rule 425 communications, 2026-04-01 — investor-call transcript (“pro forma ownership 65% Unilever / 35% McCormick”; “$15.7 billion in cash”; “$600 million annual run-rate cost synergies”; “net leverage at or below 4x at closing… approximately 3x within 2 years”; “~13.8x calendar year 2025 EBITDA for both companies”; “Reverse Morris Trust… fixed number of McCormick shares”; “secondary stock listing in Europe”; “close by mid 2027”), transaction-overview, employee FAQs, and microsite communications; subsequent 425s through 2026-06-02.
7. EDGAR XBRL company facts (companyfacts API) — multi-year revenue, margins, EPS, cash flow (OCF, capex, dividends, buybacks), balance sheet (cash, debt, goodwill/intangibles, equity), shares. Accessed 2026-06-21.
8. DEF 14A (proxy) — executive compensation structure (annual plan on adjusted-EPS / net-sales / volume / operating-income growth; long-term cumulative-net-sales plan with a relative-TSR modifier; no ROIC metric); beneficial ownership and the dual-class (MKC.V voting / MKC non-voting) control structure.
9. Form 3/4/5 (insider transactions) — Form 4 corpus parsed; one open-market purchase in the window (director Hattersley, 2,000 sh @ ~$52.98); zero CEO/CFO open-market buying; otherwise routine phantom-stock grants and dividend-reinvestment entries (Foley, directors, June 2026).
10. Form 8-K series + S-3ASR — earnings 8-Ks; the 2026-01-02 de Mexico 8-K; the 2026-02-20 S-3ASR (debt shelf); the deal-financing 8-Ks (2026-05-01 onward).

B. Primary — Company communications & transcripts

11. Q1-FY2026 earnings call transcript (~2026-03-31, via ROIC.ai) — the deal-announcement call: RMT structure, 65/35 ownership, $15.7B cash, $600M synergies (~⅔ by end of year 2, full by year 3), op margin 21%→23–25%, organic 2–3% to 3–5% via “self-help,” leverage 4x→3x, integration named the #1 risk, EPS accretion not quantified, India Foods excluded, de Mexico/Unilever mayo overlap “too early to speculate.”
12. Q4-FY2025 earnings call transcript (~2026-01-22, via ROIC.ai) — 40th consecutive annual dividend increase; FY2025 OCF $962M, dividends $483M, $0 buyback (deleveraging/IG priority); FY2026 reported-vs-organic growth bridge (de Mexico consolidation).
13. Q3-FY2025 earnings call transcript (via ROIC.ai) — “fifth consecutive quarter of volume-led growth”; China high-end-dining foodservice softness; Flavor Solutions large-CPG volume softness offset by QSR.
14. ROIC.ai financial database — income statement, balance sheet, cash flow, profitability ratios (ROIC ~8.7%, ROE ~14%), enterprise value (recomputed live at $46.64 — ROIC’s screen EV uses a stale ~$67–71 basis), valuation multiples, per-share data. Third-party aggregated; reconciled to filings.

C. Secondary — Market, factor, and price data (accessed 2026-06-21)

15. Five-year price history (split/dividend-adjusted OHLCV) — for the Stock Price Action event map; ~$95 (Apr-2022) peak → ~$45.6 (May-2026) trough → $46.64 (2026-06-18); 52-week range ~$44.8–$75.9.
16. News feed — recent items including the Toms Capital stake (~2026-06-01, scored important/positive), the UBS packaged-food “tough setup” note (2026-06-02), the “steep multi-month slump” valuation piece (2026-06-03), the Q2-FY2026 earnings date (2026-06-25), and insider-form entries. (an own-history valuation-percentile feed was glitched for MKC — TTM-EPS ~$6.10 ≈ 2x the true ~$3.00, identical 0.338 percentiles across P/E/P/B/P/S = fallback artifact; the decade-cheap own-history read was computed independently from the ROIC multiple series.)
17. FactorsToday factor model — stock-info (beta 0.196, alpha −0.216, rs_peak −50.9%, rs_12m −34.2%, div yield ~4.0%); leaderboard (deeply negative Sharpe across all horizons — y1 −1.30, y3 −0.80, y5 −0.50; lifetime max drawdown −52%); style loadings (LowVol +0.36, DividendYield +0.11, Value +0.03, Growth −0.44, InterestRate −0.24, Momentum zeroed); factor-similar peers (Consumer Staples ETFs RSPS/IYK, INGR/Ingredion, KHC, PEP).
18. Public press / web — coverage of the McCormick–Unilever Foods combination and reaction; the Toms Capital (Benjamin Pass) stake; Terry Smith / Fundsmith’s exit from Unilever (~2026-05-27) criticizing the deal structure and McCormick’s “management and returns”; Unilever’s repositioning as a home-and-personal-care pure-play (~€39B revenue) after the 2025 ice-cream (Magnum Co.) spin.

D. Peer / cohort comparables (public filings & market data)

19. Packaged-food and flavor peer set — Hershey (HSY), Kraft Heinz (KHC), Mondelez (MDLZ), Keurig Dr Pepper (KDP), Coca-Cola (KO), PepsiCo (PEP), Colgate-Palmolive (CL), and Ingredion (INGR) — public filings and market data used for the packaged-food industry structure, private-label/GLP-1 framing, the staples-cohort de-rating, and the valuation comp set (KHC ~7.8x and INGR ~6.8x EV/EBITDA at the value end; HSY ~21x and MDLZ ~18.3x at the premium end).

E. Frameworks

22. Greenwald & Kahn, Competition Demystified — barriers-to-entry / moat-type taxonomy (demand captivity vs supply/cost vs economies-of-scale-plus-captivity); market-share-stability and ROIC tests; EPV.
23. Chancellor (ed.), Capital Returns (Marathon Asset Management) — supply-side capital-cycle analysis; the asset-growth anomaly (a serial acquirer doubling its size at a trough multiple); high returns attract capital and mean-revert.

Note on confidence: figures sourced to EDGAR filings and EDGAR XBRL are treated as Fact. Deal terms are FACT, sourced to the Rule-425 investor communications and the Term Loan/Bridge 8-K (referencing the Merger Agreement dated 2026-03-31); synergy delivery, EPS accretion, and the deal’s value impact are Interpretation/Open Questions pending close (~mid-2027). Market-share and TAM figures are management/third-party estimates. The Toms Capital activist’s specific demands remain an Open Question pending any 13D/letter.